Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $0.74 in the prior trading day, Harvard Bioscience Inc (NASDAQ: HBIO) closed at $0.7, down -5.09%. In other words, the price has decreased by -$5.09 from its previous closing price. On the day, 0.52 million shares were traded. HBIO stock price reached its highest trading level at $0.7597 during the session, while it also had its lowest trading level at $0.6912.
Ratios:
Our goal is to gain a better understanding of HBIO by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.60 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.64. For the most recent quarter (mrq), Quick Ratio is recorded 0.41 and its Current Ratio is at 0.81. In the meantime, Its Debt-to-Equity ratio is 3.04 whereas as Long-Term Debt/Eq ratio is at 0.52.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HBIO now has a Market Capitalization of 31348418 and an Enterprise Value of 67316424. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.36 while its Price-to-Book (P/B) ratio in mrq is 2.23. Its current Enterprise Value per Revenue stands at 0.77 whereas that against EBITDA is 13.498.
Stock Price History:
The Beta on a monthly basis for HBIO is 1.52, which has changed by -0.6589862 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, HBIO has reached a high of $2.30, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is 22.48%, while the 200-Day Moving Average is calculated to be 39.50%.
Shares Statistics:
The stock has traded on average 6.52M shares per day over the past 3-months and 702270 shares per day over the last 10 days, according to various share statistics. A total of 44.58M shares are outstanding, with a floating share count of 38.25M. Insiders hold about 14.19% of the company’s shares, while institutions hold 36.00% stake in the company. Shares short for HBIO as of 1764288000 were 477324 with a Short Ratio of 0.07, compared to 1761868800 on 7047412. Therefore, it implies a Short% of Shares Outstanding of 477324 and a Short% of Float of 1.16.
Earnings Estimates
The performance of Harvard Bioscience Inc (HBIO) in the stock market is under the watchful eye of 2.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.0, with high estimates of $0.01 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.04 and $0.02 for the fiscal current year, implying an average EPS of $0.03. EPS for the following year is $0.09, with 2.0 analysts recommending between $0.13 and $0.06.
Revenue Estimates
2 analysts predict $23.1M in revenue for. The current quarter. It ranges from a high estimate of $23.4M to a low estimate of $22.8M. As of. The current estimate, Harvard Bioscience Inc’s year-ago sales were $24.56MFor the next quarter, 2 analysts are estimating revenue of $21.25M. There is a high estimate of $21.7M for the next quarter, whereas the lowest estimate is $20.8M.
A total of 2 analysts have provided revenue estimates for HBIO’s current fiscal year. The highest revenue estimate was $86.2M, while the lowest revenue estimate was $85.6M, resulting in an average revenue estimate of $85.9M. In the same quarter a year ago, actual revenue was $94.14MBased on 2 analysts’ estimates, the company’s revenue will be $92.1M in the next fiscal year. The high estimate is $95.6M and the low estimate is $88.6M.
